Pulmonary hypertension in systemic lupus erythematosus: A systematic review and analysis of 642 cases in Chinese population

Rheumatology International

Volumn 33, Issue 5, 2013, Pages 1211-1217

  Xia, Y K ^a   Tu, S H ^a   Hu, Y H ^a   Wang, Y ^a   Chen, Z ^a   Day, H T ^b   Ross, K ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ODS Health Plans   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Prognosis; Pulmonary hypertension; Raynaud's phenomenon; Right heart catheterization; Serous effusion; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOPROTEIN ANTIBODY; VASODILATOR AGENT;

ARTHRITIS; DIAGNOSTIC ERROR; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG PRESSURE; MEAN ARTERIAL PRESSURE; PERICARDIAL EFFUSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSTHORACIC ECHOCARDIOGRAPHY; X RAY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHINA; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84878015665     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2525-y     Document Type: Review

References (49)

1. Sanchez O, Sitbon O, Garcia G et al (2003) Pulmonary artery hypertension associated with connective tissue diseases. Presse Med 32:789-799
2. Chen LJ, Chang HC, Lu LY et al (2004) Prolonged survival after single lung transplantation for pulmonary hypertension secondary to systemic lupus erythematosus. J Chin Med Assoc 67:248-251
3. Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188:985-997 discussion 997
4. Yoshio T, Masuyama J, Sumiva M et al (1994) Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 11:2058-2063
5. Hassoun PM (2009) Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 30:429-439. doi: 10.1055/s-0029-1233312
6. Winslow TM, Ossipov MA, Fazio GP et al (1995) Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 129:510-515
7. Turner A, Samanta A, Nichol FE (1991) Primary pulmonary hypertension associated with systemic lupus erythematosus. Clin Rheumatol 10:320-322
8. Asherson RA, Higenbottam TW, Dinh Xuan AT et al (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292-1298
9. Quismorio FP Jr, Sharma O et al (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349-359
10. Kim WU, Min JK, Lee SH et al (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 17:539-545
11. Luo RQ, Lei YX, Zhang X et al (2008) Clinical analysis of patients with systemic lupus erythematosus and concomitant pulmonary hypertension. Nan Fang Yi Ke Da Xue Xue Bao 28:1860-1863
12. Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923-1929
13. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 11:1271-1277
14. Hasegawa EM, Caleiro MT, Fuller R et al (2009) The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 18:618-621. doi: 10.1177/0961203308101719
15. Frea S, Capriolo M, Marra WG et al (2011) Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. Echocardiography 28:860-869. doi: 10.1111/j.1540-8175.2011.01467.x
16. Shariff N, Kumar A, Narang R et al (2007) A study of pulmonary arterial hypertension in patients with rheumatoid arthritis. Int J Cardiol 115:75-76. doi: 10.1016/j.ijcard.2006.01.013
17. Arca Barca B, Paredes Vila S, Mazaira Riocabo A (2011) Primary pulmonary hypertension in Sjogren's syndrome: a rare association. Reumatol Clin 7:212. doi: 10.1016/j.reuma.2010.06.006
18. Cefle A, Inanc M, Sayarlioglu M et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31:183-189. doi: 10.1007/s00296-009-1255-2
19. Magliano M, Isenberg DA, Hillson J (2002) Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum 46:1997-2009. doi: 10.1002/art.10442
20. Harvey AM, Shulman LE, Tumulty PA et al (1954) Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33:291-437
21. Perez HD, Kramer N (1981) Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 11:177-181. doi: 10.1016/0049-0172(81)90098-6
22. Tanaka E, Harigai M, Tanaka M et al (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282-287
23. Prabu A, Patel K, Yee CS et al (2009) Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 48:1506-1511. doi: 10.1093/rheumatology/kep203
24. Koyama S, Ichiyoshi T, Chino M et al (1996) Systemic lupus erythematosus with pulmonary hypertension. Intern Med 35:39-42
25. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655-1665. doi: 10.1056/NEJMra035488
26. Pearson JD (2000) Normal endothelial cell function. Lupus 9:183-188
27. Humbert M, Simonneau G (2005) Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol 1:93-101. doi: 10.1038/ncprheum0048
28. Nakamura T, Ebihara I, Tomino Y et al (1995) Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47:481-489
29. Shen JY, Chen SL, Wu YX et al (1999) Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 18:147-151
30. Lian F, Chen D, Wang Y et al (2011) Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int. doi: 10.1007/s00296-011-1880-4
31. Grunig E, Ehlken N, Nagel C (2008) Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 28:225-230. doi: 08040225[pii]
32. Cefle A, Inanc M, Sayarlioglu M et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31:183-189. doi: 10.1007/s00296-009-1255-2
33. Houman MH, Smiti-Khanfir M, Ben Ghorbell I et al (2004) Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 13:204-211
34. Pope J (2008) An update in pulmonary hypertension in systemic lupus erythematosus: do we need to know about it? Lupus 17:274-277
35. Levien TL (2010) Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag 6:167-177
36. Kasparian A, Floros A, Gialafos E et al (2007) Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16:505-508. doi: 10.1177/0961203307080629
37. Denton CP, Cailes JB, Phillips GD et al (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239-243
38. Gonzalez-Lopez L, Cardona-Munoz EG, Celis A et al (2004) Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 13:105-112
39. Jais X, Launay D, Yaici A et al (2008) Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521-531. doi: 10.1002/art.23303
40. Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338-342
41. Robbins IM, Christman BW, Newman JH et al (1998) A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 114:1269-1275
42. Ahmadi-Simab K, Lamprecht P, Gross WL (2005) Successful therapy of bosentan-refractory pulmonary arterial hypertension (PH) with inhalative iloprost. Clin Exp Rheumatol 23:402-403
43. Mok MY, Tsang PL, Lam YM et al (2007) Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus 16:279-285. doi: 10.1177/0961203307076509
44. Tang TQ, Huang NS, Chen SF et al (1999) The experimental study of the effects of ligustrazine on the blood serum endothelin and on the expression of ET-1 of the lung and ETA-RmRNA of the pulmonary vascular smooth muscle cells in hypoxic rats. Chin Pharm J 34:17-20
45. Jiang Z, Liu HX, Yuan JS et al (1997) Effects of hypoxia and salvia miltiorrhiza on the secretion of endothelin and releasing of nitrogen monoxidum in pulmonary artery endothelial cell. Chin J Intern Med 36:778-779
46. Orens JB, Martinez FJ, Lynch JP (1994) Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 20:159-193
47. Chung SM, Lee CK, Lee EY et al (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25:866-872. doi: 10.1007/s10067-006-0206-5
48. Chung L, Liu J, Parsons L et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138:1383-1394. doi: 10.1378/chest.10-0260
49. Zhang R, Dai LZ, Xie WP et al (2011) Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 140:301-309. doi: 10.1378/chest.10-2327